Cannabis Science Inc. Appoints Michael McGrath, MD, PhD, Professor, Departments of Laboratory Medicine, Pathology, and Medicine, University of California, San Francisco (UCSF), and Co-Founder of Biotechs Pathologica LLC and Neuraltus Pharmaceuticals, Inc., to the Company's Scientific Advisory Board
3/28/2013 6:36:33 AM
More...
|
Neuraltus Pharmaceuticals, Inc. Announces Phase 2 Clinical Results for NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS)
10/30/2012 9:42:34 AM
More...
|
Andrew Gengos Out, John Walker in as Neuraltus Pharmaceuticals, Inc. CEO
9/12/2012 8:27:01 AM
More...
|
Drug Developer Neuraltus Pharmaceuticals, Inc. Raises $9.6 Million Toward $11 Million Goal
12/22/2011 7:36:49 AM
More...
|
Neuraltus Pharmaceuticals, Inc. Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
12/3/2010 7:25:43 AM
More...
|
Neuraltus Pharmaceuticals, Inc. Reports Clinical Results from Phase 1 NP001 Study in the Treatment of Amyotrophic Lateral Sclerosis (ALS)
11/30/2010 7:04:13 AM
More...
|
Neuraltus Pharmaceuticals, Inc. Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
11/5/2010 11:32:19 AM
More...
|
Neuraltus Pharmaceuticals, Inc. Announces Last Patient Out for Studies in ALS and Dyskinesias Associated with the Treatment of Parkinson's Disease
10/4/2010 11:25:11 AM
More...
|
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
2/8/2010 6:15:53 AM
More...
|
Neuraltus Pharmaceuticals Raises $17 Million Series A Funding
3/26/2009 7:27:57 AM
More...
|